array:21 [
  "pii" => "X2013251409004564"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full"
  "estado" => "S300"
  "fechaPublicacion" => "2009-06-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2009;29:203-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 3748
    "formatos" => array:3 [
      "EPUB" => 224
      "HTML" => 3009
      "PDF" => 515
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699509004567"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full"
      "estado" => "S300"
      "fechaPublicacion" => "2009-06-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2009;29:203-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 10013
        "formatos" => array:3 [
          "EPUB" => 231
          "HTML" => 9115
          "PDF" => 667
        ]
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "titulo" => "Propiedades cardiometabólicas del Manidipino: ¿Más allá de la reducción de la presión arterial?"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "203"
            "paginaFinal" => "207"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Cardio-metabolic properties of manidipine: beyond lowering arterial pressure?"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Nisa Buset Ríos, Francisco Rodríguez Esparragón, José Carlos Rodríguez Pérez"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "Nisa"
                "apellidos" => "Buset Ríos"
              ]
              1 => array:2 [
                "nombre" => "Francisco"
                "apellidos" => "Rodríguez Esparragón"
              ]
              2 => array:2 [
                "nombre" => "José Carlos"
                "apellidos" => "Rodríguez Pérez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251409004564"
          "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004564?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004567?idApp=UINPBA000064"
      "url" => "/02116995/0000002900000003/v0_201502091409/X0211699509004567/v0_201502091409/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251409004638"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.3.5152.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-06-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2009;29:208-13"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5011
      "formatos" => array:3 [
        "EPUB" => 255
        "HTML" => 4138
        "PDF" => 618
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Fibrate-induced deterioration of renal function"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "208"
          "paginaFinal" => "213"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Deterioro de Función Renal Inducido por Fibratos"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "17218078_f1_p209.jpg"
              "Alto" => 252
              "Ancho" => 397
              "Tamanyo" => 21230
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Natalia Polanco, E. Hernández, E. González, E. Gutiérrez Martínez, I. Bello, V. Gutiérrez-Millet, F. García, E. Morales, M. Praga"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "Natalia"
              "apellidos" => "Polanco"
            ]
            1 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Hernández"
            ]
            2 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "González"
            ]
            3 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Gutiérrez Martínez"
            ]
            4 => array:2 [
              "Iniciales" => "I."
              "apellidos" => "Bello"
            ]
            5 => array:2 [
              "Iniciales" => "V."
              "apellidos" => "Gutiérrez-Millet"
            ]
            6 => array:2 [
              "Iniciales" => "F."
              "apellidos" => "García"
            ]
            7 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Morales"
            ]
            8 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Praga"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509004630"
        "doi" => "10.3265/Nefrologia.2009.29.3.5152.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004630?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004638?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004638/v0_201502091629/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251409004556"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.3.5290.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-06-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2009;29:196-202"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4383
      "formatos" => array:3 [
        "EPUB" => 236
        "HTML" => 3648
        "PDF" => 499
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "FGF23 in chronic kidney disease and kidney post-transplant patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "196"
          "paginaFinal" => "202"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "El FGF23 en la insuficiencia renal crónica y el post-transplante renal"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "17018078_f1_p198.jpg"
              "Alto" => 337
              "Ancho" => 398
              "Tamanyo" => 16798
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Armando Luis Negri"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Armando Luis"
              "apellidos" => "Negri"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509004559"
        "doi" => "10.3265/Nefrologia.2009.29.3.5290.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004559?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004556?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004556/v0_201502091629/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Cardio-metabolic properties of manidipine: beyond lowering arterial pressure?"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "203"
        "paginaFinal" => "207"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Nisa Buset Ríos, Francisco Rodríguez Esparragón, José Carlos Rodríguez Pérez"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "Nisa"
            "apellidos" => "Buset Ríos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Francisco"
            "apellidos" => "Rodr&#237;guez Esparrag&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Jos&#233; Carlos"
            "apellidos" => "Rodr&#237;guez P&#233;rez"
            "email" => array:1 [
              0 => "jrodperd&#64;gobiernodecanarias&#46;org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Unidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Unidad de Investigación, Servicio de Nefrología, Hospital Universitario de Gran Canaria Dr. Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Propiedades cardiometab&#243;licas del Manidipino&#58; &#191;M&#225;s all&#225; de la reducci&#243;n de la presi&#243;n arterial&#63;"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "17118078_f1_p205.jpg"
            "Alto" => 434
            "Ancho" => 824
            "Tamanyo" => 24773
          ]
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Hypertension and insulin resistance are the most important risk factors for cardiovascular damage&#46;<span class="elsevierStyleSup">1&#44;2</span> Antihypertensive treatment commonly includes the combination of calcium channel antagonists &#40;CA&#41; with angiotensin converting enzyme inhibitors &#40;ACE inhibitors&#41; or angiotensin II receptor blockers &#40;ARBs&#41;&#44;<span class="elsevierStyleSup">3</span> since single-agent treatment is not able to reduce blood pressure in most cases&#46;</p><p class="elsevierStylePara">Some studies<span class="elsevierStyleSup">4&#44;5</span> show that anti-hypertensive treatments that include calcium antagonists improve insulin sensitivity&#46; In a study of 158 hypertensive patients with type-2 diabetes&#44; the combination of manidipine and delapril showed results similar to those of olmesartan and hydrochlorothiazide as far as reducing arterial pressure&#44; but with fewer changes in orthostatic arterial pressure&#44; as well as fewer adverse metabolic effects&#46; These data are more interesting for this group of patients&#44; which is especially prone to orthostatic hypotension associated with an increase in morbidity and mortality&#46;<span class="elsevierStyleSup">5</span></p><p class="elsevierStylePara">Preliminary studies of diabetic patients with uncontrolled hypertension and microalbuminuria suggest that&#44; despite adequate treatment with ACE inhibitors or ARBs&#44; manidipine may be given in combination with the renin-angiotensin inhibitors to normalise blood pressure and urinary excretion of albumin in diabetic patients&#46;<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">Calcium antagonists constitute a highly heterogeneous class of molecules that may be grouped into phenylalkylamine derivatives&#44; such as verapamil&#44; benzothiazepine derivatives whose prototype is diltiazem&#44; and 1&#44;4-dihydropyridine compounds that include manidipine&#46;<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">The first generation of dihydropyridine calcium channel blockers&#44; such as nifedipine&#44; are characterised by their instant release&#44; their short half-life and their rapid absorption&#46; Despite having a favourable metabolic profile&#44; they present some adverse effects&#44; such as sudden drops in arterial pressure&#44; tachycardia and sympathetic activation&#46; In the second generation&#44; that includes amongst others&#44; felodipine and isradipine is characterised by a slower molecular release&#46;<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">The latest generation of calcium antagonists&#44; with a long half-life and extended duration of action has shown a clear decrease in arterial pressure and a significant reduction in side effects&#46; On this subject&#44; a trial with 30 obese hypertensive patients treated with amlodipine&#44; manidipine and cilnidipine revealed that these long-acting calcium antagonists reduce arterial pressure&#44; and in addition&#44; reduce insulin resistance&#44; suggesting important cardio-metabolic properties&#46;<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">VOLTAGE-DEPENDENT CALCIUM CHANNELS</span></p><p class="elsevierStylePara">Voltage-dependent calcium channels are classified according to their pharmacological and electrophysiological properties as L&#44; P&#47;Q&#44; N&#44; R and T-type&#46;<span class="elsevierStyleSup">9</span> They are composed of multiple heteromeric subunits&#58; &#945;&#44; &#946;&#44; &#947; &#948;&#46; The &#945;1 subunit seems to be responsible for the prinicipal characteristics of these channels&#46;<span class="elsevierStyleSup">10-12</span></p><p class="elsevierStylePara">Unlike the first calcium antagonists that only blocked L-type channels&#44; third-generation blockers&#44; such as manidipine&#44; lercadipine&#44; amlodipine&#44; nivaldipine or efonidipine&#44; are capable of blocking both L-type and T-type channels&#44; the latter are only active during cellular proliferation&#46;</p><p class="elsevierStylePara">L-type channels are activated by intense depolarisations&#44; resulting in a prolonged calcium influx in a large variety of cell types&#46; In this way&#44; they play a central role in the contraction of cardiac and smooth muscle cells &#40;Cav1&#46;2&#91;&#945;<span class="elsevierStyleInf">1C</span>&#93;&#41;&#44; are responsible for arterial smooth muscle tone&#44; and have become pharmacological targets in the treatment of hypertension and angina&#46; In the kidney&#44; &#40;Cav1&#46;2&#91;&#945;<span class="elsevierStyleInf">1C</span>&#93; and Cav1&#46;3&#91;&#945;<span class="elsevierStyleInf">1D</span>&#93;&#41; they promote the dilatation of pre-glomerular or afferent arterioles&#44; increasing glomerular hypertension by a considerably&#46; Furthermore&#44; we find other L-type channels in skeletal muscle Cav1&#46;1&#40;&#945;<span class="elsevierStyleInf">1S</span>&#41;&#44; brain and kidney &#40;Cav1&#46;2&#91;&#945;<span class="elsevierStyleInf">1C</span>&#93;&#44; Cav1&#46;3&#91;&#945;<span class="elsevierStyleInf">1D</span>&#93;&#41;&#44; pancreas &#40;Cav1&#46;3&#91;&#945;<span class="elsevierStyleInf">1D&#93;</span>&#41; and retina &#40;Cav1&#46;4&#91;&#945;<span class="elsevierStyleInf">1F</span>&#93;&#41;&#46;<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">T-channels are expressed in the nervous system &#40;Cav3&#46;1&#91;&#945;<span class="elsevierStyleInf">1G</span>&#93;&#41;&#44; brain &#40;Cav3&#46;1&#91;&#945;<span class="elsevierStyleInf">1G</span>&#93;&#44; Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93; and Cav3&#46;3&#91;&#945;<span class="elsevierStyleInf">1D</span>&#93;&#41;&#44; heart &#40;Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93;&#41;&#44; kidney &#40;Cav3&#46;1&#91;&#945;<span class="elsevierStyleInf">1G</span>&#93;&#44; Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93;&#41; and liver &#40;Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93;&#41;&#46;<span class="elsevierStyleSup">9</span> Their influence in hormone secretion such as renin&#44; aldosterone&#44; atrial natriuretic peptide and insulin has been suggested in multiple occasions&#46; T-type channels are activated by short depolarisations&#44; which provoke a transitory flow of calcium&#46; In post-glomerular or efferent arterioles&#44; only T-type channels and no L-type channels are expressed and this implies that their tone must be controlled by T channels and AT1 angiotensin II receptors&#46; Manidipine and lercanidipine block T-type channels in efferent arterioles&#44; thus diminishing the intraglomerular pressure and also the excretion of albumin&#59; at the same time&#44; they block L-type channels&#44; favouring afferent arteriole dilation&#46; In this way&#44; T-type channel antagonists influence renal haemodynamics through their anti-hypertensive action&#46;<span class="elsevierStyleSup">9&#44;13-15</span> We can therefore consider their effect to be protective against renal damage&#44; since the kidney is one of the targets for end-organ damage in hypertensive and diabetic patients&#46;</p><p class="elsevierStylePara">Non-haemodynamic action of T-type channel antagonists may have multiple beneficial effects by inhibiting inflammatory processes &#40;inhibition of Rho kinase&#44; NF-kB&#44; leukocyte adhesion&#41; and blocking the renin-angiotensin system and the sympathetic nervous system&#46;<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Apart from L and T-type channels&#44; P&#47;Q type channels are found in the brain&#44; kidneys and pituitary gland &#40;&#91;Cav2&#46;1&#40;&#945;<span class="elsevierStyleInf">1A</span>&#41;&#93;&#44; N-type channels are found in the brain and nervous system &#40;Cav2&#46;2&#91;&#945;<span class="elsevierStyleInf">1B</span>&#93;&#41; and R-type channels in the brain&#44; heart and pituitary gland &#40;Cav2&#46;3&#91;&#945;<span class="elsevierStyleInf">1E</span>&#93;&#41;&#46;<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">MANIDIPINE&#44; ADIPOGENESIS AND INSULIN SENSITIVITY</span></p><p class="elsevierStylePara">The lipotoxicity hypothesis suggests that in type-2 diabetes the adipose tissue looses the ability to accommodate an excess of calories&#46; The loss of adipocyte differentiation causes the excess of calories to accumulate&#44; mainly in the liver&#44; pancreas and muscle tissue&#44; which contributes to the development of insulin resistance&#46;<span class="elsevierStyleSup">16</span> Small adipocytes are sensitive to insulin&#44; unlike the mature ones&#44; which become hypertrophied and insulin-resistant&#46;Therefore&#44; favouring adipogenesis will contribute to lowering insulin resistance in type-2 diabetics&#46;</p><p class="elsevierStylePara">The improvement of insulin sensitivity gained with dihydropyridine calcium antagonists is almost imperceptible&#46;</p><p class="elsevierStylePara">Nifedipine&#44; only blocks L-type channels&#44; worsens insulin resistance and inhibits the release of glucose&#46;<span class="elsevierStyleSup">4</span> However&#44; studies with manidipine show surprising results in this respect&#46; It has already been shown in a randomised clinical trial of 64 hypertensive patients with metabolic syndrome&#44; evaluated according to NCEP&#47;ATPIII criteria&#44; treated with manidipine or amlodipine during 12 weeks that although similar decreases in arterial pressure were observed with both treatments&#44; only the patients treated with manidipine show a significant reduction in insulin resistance&#46;<span class="elsevierStyleSup">17</span> Similarly&#44; the most recent analysis of the effects of the combination of delapril&#47;manidipine compared with olmesartan&#47;hydrochlorothiazide on insulin sensitivity and plasma fibrinogen in obese hypertensive patients showed that the first combination significantly reduced insulin resistance and plasma fibrinogen levels&#44; despite the fact that the decrease in arterial pressure values was similar for both combinations&#46;<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">Studies by others have shown that manidipine&#44; but not amlodipine or lercadipine&#44; activates the peroxisome proliferator-activated receptor &#40;PPAR&#947;&#41; in 3T3-L1 adipocytes in the rat&#46;<span class="elsevierStyleSup">19&#44;20</span> In our studies of NIH-3T3 cells treated with manidipine&#44; we observed an increase in the expression of both PPAR&#947; and the adipocyte differentiation 2 &#40;aP2&#41; gene&#46; The latter is an indicator of adipogenesis and possibly expressed after induction of the former &#40;figure 1&#41;&#46; These results suggest that manidipine increases insulin sensitivity in hypertensive diabetic patients by stimulating the formation of new adipocytes &#40;unpublished observations&#41;&#46; In addition it has been observed that the increase in intracellular calcium inhibits pre-adipocyte differentiation&#46;<span class="elsevierStyleSup">21</span> This is distinct from the well known role of calcium in more rapid processes&#44; such as neurosecretion&#44; excitation or contraction&#46;</p><p class="elsevierStylePara">Adipogenesis&#44; like other differentiation processes&#44; depends on transcription factor promoters such as PPAR&#947; and transcription factor inhibitors&#44; such as the GATA family&#44; which in turn are activated by extracellular signals&#46; Calcium homeostasis was studied with particular attention to the calreticulin&#44; the principal protein that binds to calcium in the lumen of the endoplasmic reticulum&#44; and which is largely responsible for rapid calcium exchange&#46; A study of stem cells and 3T3-L1 pre-adipocytes shows that calreticulin could modulate adipogenesis by means of a negative feedback mechanism&#46; PPAR&#947; is a potent calreticulin transcription activator&#44; since it binds to its promoter&#46; In this way&#44; it increases calreticulin expression&#44; but once calreticulin is over-expressed&#44; it inhibits cis binding of the PPAR&#947;-RxR heterodimer to PPAR&#947; response elements &#40;PPRE&#41;&#44; cancelling transcriptional activation of PPAR&#947; by fatty acids&#46; By this mechanism&#44; calreticulin negatively regulates both the expression of PPAR&#947; and other critical pro-adipogenic transcription factors such as C&#47;EBP&#945;&#46;<span class="elsevierStyleSup">22</span></p><p class="elsevierStylePara">The action of manidipine as a calcium channel blocker may prevent calcium from entering the cell thus&#44; decreasing the concentration of calcium in the endoplasmic reticulum and therefore&#44; the concentration of calreticulin&#44; favouring adipocyte differentiation&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MANIDIPINE&#58; ANTI-INFLAMMATORY&#44; VASOPROTECTIVE AND ANTIOXIDANT EFFECTS</span></p><p class="elsevierStylePara">Oxidative stress plays a fundamental role in the development of atherosclerosis&#46; Several studies demonstrate the beneficial effect of dihydropiridine calcium antagonists on atherosclerotic lesions&#46;<span class="elsevierStyleSup">23</span> The beneficial effects of calcium blockers in macrovascular endothelial cells should be demonstrated and proved using mechanisms that do not include calcium channels&#44; since these are not expressed in endothelial cells&#46;<span class="elsevierStyleSup">24</span> For this reason&#44; some authors have speculated that the action of dihydropyridines on this tissue was related with their lipophilic nature&#46;<span class="elsevierStyleSup">25</span> Toba et al&#46; point out the antioxidant&#44; anti-inflammatory effect of manidipine and other third-generation calcium antagonists such as amlodipine&#44; measured by the increase of expression of endothelial nitrous oxide synthase &#40;eNOS&#41; and the inhibition of the expression of angiotensin converter enzyme &#40;ACE&#41; &#44; but not by its possible action of lowering arterial pressure &#46; In this study&#44; we observe that manidipine normalises the decrease in both the eNOS gene and its protein&#44; and attenuates the over-expression of NAPDH oxidase&#44; VCAM and MCP-1 in the aorta of hypertensive rats&#46;<span class="elsevierStyleSup">26</span></p><p class="elsevierStylePara">Furthermore&#44; manidipine shows another beneficial effect on atherogenesis&#44; since it inhibits the expression of LOX-1&#44; a low-density lipoprotein receptor induced by angiotensin II&#46;<span class="elsevierStyleSup">27</span></p><p class="elsevierStylePara">Sun X et al<span class="elsevierStyleSup">28</span> recently showed that in differentiated mature adipocytes&#44; 3T3-L1 or co-cultures with both cell types&#44; calcitriol increases expression of inflammatory molecules such as MCP-1&#44; MIF&#44; M-CSF&#44; MIP&#44; IL-6&#44; TNF or CD14&#46; Treatment with nifedipine or dinitrophenol inhibits the action of the calcitriol&#44; which reveals a mechanism that is dependent on calcium and mitochondrial uncoupling&#46; Therefore&#44; it would seem that blocking calcium channels with manidipine would produce an antioxidant&#44; antiinflammatory effect by lowering the intracellular calcium level&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">KEY CONCEPTS</span></p><p class="elsevierStylePara">1&#46; Voltage-dependent calcium channels are classified according to their pharmacological and electrophysiological properties as L&#44; P&#47;Q&#44; N&#44; R and T-type&#46; They are composed of multiple heteromeric subunits&#58; &#945;&#44; &#946;&#44; &#947; and &#948;&#46; The &#945;1 subunit seems to be responsible for principal characteristic of these channels&#46;</p><p class="elsevierStylePara">2&#46; L-type channels are activated by intense depolarisations that are responsible for the tone of smooth arterial muscle&#46; Ttype channels are activated by short depolarisations&#44; which provoke a transitory flow of calcium&#46;</p><p class="elsevierStylePara">3&#46; Although the improvement in insulin sensitivity achieved with dihydropyridine calcium antagonists is almost imperceptible&#44; we have observed an increase in the relative expression of PPAR&#947; &#40;peroxisome proliferator-activated receptor&#41; and the relative expression of the adipocyte differentiation 2 &#40;aP2&#41; gene&#46; These preliminary results may suggest that manidipine increases insulin sensitivity in hypertensive diabetic patients by stimulating the formation of new adipocytes and preserving PPAR&#947; activity&#46;</p><p class="elsevierStylePara"><a href="grande&#47;17118078&#95;f1&#95;p205&#46;jpg" class="elsevierStyleCrossRefs"><img src="17118078_f1_p205.jpg"></img></a></p><p class="elsevierStylePara">Figure 1&#46; </p>"
    "pdfFichero" => "P-E-S-A171-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec440023"
          "palabras" => array:1 [
            0 => "Resistencia a la insulina"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec440025"
          "palabras" => array:1 [
            0 => "Manidipino"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec440027"
          "palabras" => array:1 [
            0 => "Calcioantagonistas"
          ]
        ]
      ]
      "en" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec440024"
          "palabras" => array:1 [
            0 => "Insulin resistance"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec440026"
          "palabras" => array:1 [
            0 => "Manidipine"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec440028"
          "palabras" => array:1 [
            0 => "Calcium antagonists"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Desde su introducci&#243;n en la d&#233;cada de los 70&#44; la evoluci&#243;n de los calcioantagonistas ha permitido solventar la incertidumbre inicialmente generada por aquellos f&#225;rmacos de primera generaci&#243;n&#46; &#201;stos se caracterizan por una menor disponibilidad oral&#44; una acci&#243;n vasodilatadora r&#225;pida y corta acci&#243;n&#46; El manidipino surge como un derivado dihidropirid&#237;nico de tercera generaci&#243;n con ventajas adicionales reales frente a las generaciones anteriores&#44; como son su alta lipofilicidad&#44; su acci&#243;n m&#225;s prolongada y una vida media prolongada a nivel del receptor y&#44; adem&#225;s&#44; algunas ventajas te&#243;ricas entre otras&#44; mejoras sobre la funci&#243;n renal reduciendo la presi&#243;n intraglomerular y la microalbuminuria&#46; Sin embargo&#44; la evaluaci&#243;n cl&#237;nica de estas &#250;ltimas propiedades depende a&#250;n de los resultados que se deriven de la experiencia cl&#237;nica&#46; Adem&#225;s de ahondar en su papel en la reducci&#243;n de la presi&#243;n arterial&#44; presentamos una breve revisi&#243;n sobre nuevos aspectos cardiometab&#243;licos de los calcioantagonistas dihidropirid&#237;nicos&#44; centr&#225;ndonos en el manidipino&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">From its introduction in the decade of the 70&#8217;s the evolution of the calcium channel blockers has allowed to resolve the uncertainty initially generated by those first generation drugs&#46; These&#44; are characterized by a smaller oral availability&#44; a fast vasodilator action and a short duration of action&#46; Manidipine arises as a dihydropyridine calcium antagonist of third generation with real additional advantages regarding to previous generations&#46; They show high lipophilia&#44; a more prolonged action and as well as a prolonged average life at the level of his receptor and&#44; in addition&#44; some theoretical advantages among others calcium antagonists&#44; improvements on the renal function by reducing the intraglomerular pressure and microalbuminuria&#46; Nevertheless&#44; the clinical evaluation of these last properties still depends on the results derived from clinical trials&#46; Besides to go deep in its role in their antihypertensive effect&#44; we presented a brief review on new cardiometabolic aspects of these dihydropyridines calcium antagonists focusing in manidipine&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "17118078_f1_p205.jpg"
            "Alto" => 434
            "Ancho" => 824
            "Tamanyo" => 24773
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:28 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J.Am.Board Fam.Med. 2008; 21: 562-568 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18988724" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Yoshinaga M, Sameshima K, Tanaka Y et al. Association between the number of cardiovascular risk factors and each risk factor level in elementary school children. Circ.J. 2008; 72: 1594-1597 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18756035" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern.Med. 2004; 43: 561-565 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15335180" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens.Res. 2008; 31: 43-50 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18360017" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65 Suppl 2: 29-39 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16398060" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N.Engl.J.Med. 1999; 341: 1447-1457"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J.Renin.Angiotensin.Aldosterone.Syst. 2008; 9: 1-9 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18404602" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ.Res. 2007; 100: 342-353 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17307972" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov NM. Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit. Proc.Natl.Acad.Sci.U.S.A 2006; 103: 17024-17029 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17071743" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Abernethy DR, Soldatov NM. Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. J.Pharmacol.Exp.Ther. 2002; 300: 724-728"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bergh JJ, Shao Y, Puente E, Duncan RL, Farach-Carson MC. Osteoblast Ca(2+) permeability and voltage-sensitive Ca(2+) channel expression is temporally regulated by 1,25-dihydroxyvitamin D(3). Am.J.Physiol Cell Physiol 2006; 290: C822-C831"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hayashi K, Wakino S, Homma K, Sugano N, Saruta T. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J.Pharmacol.Sci. 2005; 99: 221-227 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16293936" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Martinez Martin FJ. [Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine]. Nefrologia. 2007; 27 Suppl 6: 26-35 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18225601" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10720594" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12411451" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Martinez Martin FJ. Manidipne (but not amlodipine), increases insulin sensitivity and rises plasma adiponectin cocentrations in hypertensive non-diabetic patients with metabolic syndrome and impaired fasting glucose. Diabetologia 2005; 48 Suppl 1: A374"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern.Med. 2008; 47: 361-366 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18310964" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nakami T, Martinez MFJ. Manidipine prevents hepatic C-reactive protein production and reactive oxygen species generation by down-regulation of the age receptor expression, dependent on PPAR-gamma activation. Journal of Hypertension 2007; 25: S119-S120"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Oshimura H, Nakami T, Javier MF. Manidipine has a marked non-haemodynamic nephroprotective action; Partly dependent on PPAR-gamma activation, and synergistic with angiotensin receptor blockade. Journal of Hypertension 2007; 25: S8"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Meldolesi J. Inhibition of adipogenesis: a new job for the ER Ca2+ pool. J.Cell Biol. 2008; 182: 11-13 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18606853" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Szabo E, Qiu Y, Baksh S, Michalak M, Opas M. Calreticulin inhibits commitment to adipocyte differentiation. J.Cell Biol. 2008; 182: 103-116 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18606846" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Simon A, Levenson J. Effects of calcium channel blockers on atherosclerosis: new insights. Acta Cardiol. 2002; 57: 249-255 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12222691" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Adams DJ, Barakeh J, Laskey R, Van Breemen C. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J. 1989; 3: 2389-2400 <a href="http://www.ncbi.nlm.nih.gov/pubmed/2477294" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Berkels R, Breitenbach T, Bartels H et al. Different antioxidative potencies of dihydropyridine calcium channel modulators in various models. Vascul.Pharmacol. 2005; 42: 145-152 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15820440" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Toba H, Nakagawa Y, Miki S et al. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens.Res. 2005; 28: 689-700 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16392774" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Toba H, Shimizu T, Miki S et al. Calcium [corrected] channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens.Res. 2006; 29: 105-116 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16755144" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sun X, Zemel MB. Calcitriol and calcium regulate cytokine production and adipocyte-macrophage cross-talk. J.Nutr.Biochem. 2008; 19: 392-399 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17869082" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004564/v0_201502091629/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35445"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Short Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000003/v0_201502091629/X2013251409004564/v0_201502091629/en/P-E-S-A171-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004564?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Cardio-metabolic properties of manidipine: beyond lowering arterial pressure?
Propiedades cardiometabólicas del Manidipino: ¿Más allá de la reducción de la presión arterial?
Nisa Buset Ríosa, Francisco Rodríguez Esparragóna, José Carlos Rodríguez Pérezb
a Unidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España,
b Unidad de Investigación, Servicio de Nefrología, Hospital Universitario de Gran Canaria Dr. Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España,
Read
8516
Times
was read the article
2551
Total PDF
5965
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251409004564"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full"
  "estado" => "S300"
  "fechaPublicacion" => "2009-06-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:203-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 3748
    "formatos" => array:3 [
      "EPUB" => 224
      "HTML" => 3009
      "PDF" => 515
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699509004567"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full"
      "estado" => "S300"
      "fechaPublicacion" => "2009-06-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2009;29:203-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 10013
        "formatos" => array:3 [
          "EPUB" => 231
          "HTML" => 9115
          "PDF" => 667
        ]
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "titulo" => "Propiedades cardiometab&#243;licas del Manidipino&#58; &#191;M&#225;s all&#225; de la reducci&#243;n de la presi&#243;n arterial&#63;"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "203"
            "paginaFinal" => "207"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Cardio-metabolic properties of manidipine&#58; beyond lowering arterial pressure&#63;"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Nisa Buset R&#237;os, Francisco Rodr&#237;guez Esparrag&#243;n, Jos&#233; Carlos Rodr&#237;guez P&#233;rez"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "Nisa"
                "apellidos" => "Buset R&#237;os"
              ]
              1 => array:2 [
                "nombre" => "Francisco"
                "apellidos" => "Rodr&#237;guez Esparrag&#243;n"
              ]
              2 => array:2 [
                "nombre" => "Jos&#233; Carlos"
                "apellidos" => "Rodr&#237;guez P&#233;rez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251409004564"
          "doi" => "10.3265/Nefrologia.2009.29.3.5078.en.full"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004564?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004567?idApp=UINPBA000064"
      "url" => "/02116995/0000002900000003/v0_201502091409/X0211699509004567/v0_201502091409/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251409004638"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.3.5152.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-06-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:208-13"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5011
      "formatos" => array:3 [
        "EPUB" => 255
        "HTML" => 4138
        "PDF" => 618
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Fibrate-induced deterioration of renal function"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "208"
          "paginaFinal" => "213"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Deterioro de Funci&#243;n Renal Inducido por Fibratos"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "17218078_f1_p209.jpg"
              "Alto" => 252
              "Ancho" => 397
              "Tamanyo" => 21230
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Natalia Polanco, E. Hern&#225;ndez, E. Gonz&#225;lez, E. Guti&#233;rrez Mart&#237;nez, I. Bello, V. Guti&#233;rrez-Millet, F. Garc&#237;a, E. Morales, M. Praga"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "Natalia"
              "apellidos" => "Polanco"
            ]
            1 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Hern&#225;ndez"
            ]
            2 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Gonz&#225;lez"
            ]
            3 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Guti&#233;rrez Mart&#237;nez"
            ]
            4 => array:2 [
              "Iniciales" => "I."
              "apellidos" => "Bello"
            ]
            5 => array:2 [
              "Iniciales" => "V."
              "apellidos" => "Guti&#233;rrez-Millet"
            ]
            6 => array:2 [
              "Iniciales" => "F."
              "apellidos" => "Garc&#237;a"
            ]
            7 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Morales"
            ]
            8 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Praga"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509004630"
        "doi" => "10.3265/Nefrologia.2009.29.3.5152.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004630?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004638?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004638/v0_201502091629/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251409004556"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.3.5290.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-06-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:196-202"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4383
      "formatos" => array:3 [
        "EPUB" => 236
        "HTML" => 3648
        "PDF" => 499
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "FGF23 in chronic kidney disease and kidney post-transplant patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "196"
          "paginaFinal" => "202"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "El FGF23 en la insuficiencia renal cr&#243;nica y el post-transplante renal"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "17018078_f1_p198.jpg"
              "Alto" => 337
              "Ancho" => 398
              "Tamanyo" => 16798
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Armando Luis Negri"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Armando Luis"
              "apellidos" => "Negri"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509004559"
        "doi" => "10.3265/Nefrologia.2009.29.3.5290.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509004559?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004556?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004556/v0_201502091629/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Cardio-metabolic properties of manidipine&#58; beyond lowering arterial pressure&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "203"
        "paginaFinal" => "207"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Nisa Buset R&#237;os, Francisco Rodr&#237;guez Esparrag&#243;n, Jos&#233; Carlos Rodr&#237;guez P&#233;rez"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "Nisa"
            "apellidos" => "Buset R&#237;os"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Francisco"
            "apellidos" => "Rodr&#237;guez Esparrag&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Jos&#233; Carlos"
            "apellidos" => "Rodr&#237;guez P&#233;rez"
            "email" => array:1 [
              0 => "jrodperd&#64;gobiernodecanarias&#46;org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Unidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Unidad de Investigación, Servicio de Nefrología, Hospital Universitario de Gran Canaria Dr. Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Propiedades cardiometab&#243;licas del Manidipino&#58; &#191;M&#225;s all&#225; de la reducci&#243;n de la presi&#243;n arterial&#63;"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "17118078_f1_p205.jpg"
            "Alto" => 434
            "Ancho" => 824
            "Tamanyo" => 24773
          ]
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Hypertension and insulin resistance are the most important risk factors for cardiovascular damage&#46;<span class="elsevierStyleSup">1&#44;2</span> Antihypertensive treatment commonly includes the combination of calcium channel antagonists &#40;CA&#41; with angiotensin converting enzyme inhibitors &#40;ACE inhibitors&#41; or angiotensin II receptor blockers &#40;ARBs&#41;&#44;<span class="elsevierStyleSup">3</span> since single-agent treatment is not able to reduce blood pressure in most cases&#46;</p><p class="elsevierStylePara">Some studies<span class="elsevierStyleSup">4&#44;5</span> show that anti-hypertensive treatments that include calcium antagonists improve insulin sensitivity&#46; In a study of 158 hypertensive patients with type-2 diabetes&#44; the combination of manidipine and delapril showed results similar to those of olmesartan and hydrochlorothiazide as far as reducing arterial pressure&#44; but with fewer changes in orthostatic arterial pressure&#44; as well as fewer adverse metabolic effects&#46; These data are more interesting for this group of patients&#44; which is especially prone to orthostatic hypotension associated with an increase in morbidity and mortality&#46;<span class="elsevierStyleSup">5</span></p><p class="elsevierStylePara">Preliminary studies of diabetic patients with uncontrolled hypertension and microalbuminuria suggest that&#44; despite adequate treatment with ACE inhibitors or ARBs&#44; manidipine may be given in combination with the renin-angiotensin inhibitors to normalise blood pressure and urinary excretion of albumin in diabetic patients&#46;<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">Calcium antagonists constitute a highly heterogeneous class of molecules that may be grouped into phenylalkylamine derivatives&#44; such as verapamil&#44; benzothiazepine derivatives whose prototype is diltiazem&#44; and 1&#44;4-dihydropyridine compounds that include manidipine&#46;<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">The first generation of dihydropyridine calcium channel blockers&#44; such as nifedipine&#44; are characterised by their instant release&#44; their short half-life and their rapid absorption&#46; Despite having a favourable metabolic profile&#44; they present some adverse effects&#44; such as sudden drops in arterial pressure&#44; tachycardia and sympathetic activation&#46; In the second generation&#44; that includes amongst others&#44; felodipine and isradipine is characterised by a slower molecular release&#46;<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">The latest generation of calcium antagonists&#44; with a long half-life and extended duration of action has shown a clear decrease in arterial pressure and a significant reduction in side effects&#46; On this subject&#44; a trial with 30 obese hypertensive patients treated with amlodipine&#44; manidipine and cilnidipine revealed that these long-acting calcium antagonists reduce arterial pressure&#44; and in addition&#44; reduce insulin resistance&#44; suggesting important cardio-metabolic properties&#46;<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">VOLTAGE-DEPENDENT CALCIUM CHANNELS</span></p><p class="elsevierStylePara">Voltage-dependent calcium channels are classified according to their pharmacological and electrophysiological properties as L&#44; P&#47;Q&#44; N&#44; R and T-type&#46;<span class="elsevierStyleSup">9</span> They are composed of multiple heteromeric subunits&#58; &#945;&#44; &#946;&#44; &#947; &#948;&#46; The &#945;1 subunit seems to be responsible for the prinicipal characteristics of these channels&#46;<span class="elsevierStyleSup">10-12</span></p><p class="elsevierStylePara">Unlike the first calcium antagonists that only blocked L-type channels&#44; third-generation blockers&#44; such as manidipine&#44; lercadipine&#44; amlodipine&#44; nivaldipine or efonidipine&#44; are capable of blocking both L-type and T-type channels&#44; the latter are only active during cellular proliferation&#46;</p><p class="elsevierStylePara">L-type channels are activated by intense depolarisations&#44; resulting in a prolonged calcium influx in a large variety of cell types&#46; In this way&#44; they play a central role in the contraction of cardiac and smooth muscle cells &#40;Cav1&#46;2&#91;&#945;<span class="elsevierStyleInf">1C</span>&#93;&#41;&#44; are responsible for arterial smooth muscle tone&#44; and have become pharmacological targets in the treatment of hypertension and angina&#46; In the kidney&#44; &#40;Cav1&#46;2&#91;&#945;<span class="elsevierStyleInf">1C</span>&#93; and Cav1&#46;3&#91;&#945;<span class="elsevierStyleInf">1D</span>&#93;&#41; they promote the dilatation of pre-glomerular or afferent arterioles&#44; increasing glomerular hypertension by a considerably&#46; Furthermore&#44; we find other L-type channels in skeletal muscle Cav1&#46;1&#40;&#945;<span class="elsevierStyleInf">1S</span>&#41;&#44; brain and kidney &#40;Cav1&#46;2&#91;&#945;<span class="elsevierStyleInf">1C</span>&#93;&#44; Cav1&#46;3&#91;&#945;<span class="elsevierStyleInf">1D</span>&#93;&#41;&#44; pancreas &#40;Cav1&#46;3&#91;&#945;<span class="elsevierStyleInf">1D&#93;</span>&#41; and retina &#40;Cav1&#46;4&#91;&#945;<span class="elsevierStyleInf">1F</span>&#93;&#41;&#46;<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">T-channels are expressed in the nervous system &#40;Cav3&#46;1&#91;&#945;<span class="elsevierStyleInf">1G</span>&#93;&#41;&#44; brain &#40;Cav3&#46;1&#91;&#945;<span class="elsevierStyleInf">1G</span>&#93;&#44; Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93; and Cav3&#46;3&#91;&#945;<span class="elsevierStyleInf">1D</span>&#93;&#41;&#44; heart &#40;Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93;&#41;&#44; kidney &#40;Cav3&#46;1&#91;&#945;<span class="elsevierStyleInf">1G</span>&#93;&#44; Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93;&#41; and liver &#40;Cav3&#46;2&#91;&#945;<span class="elsevierStyleInf">1H</span>&#93;&#41;&#46;<span class="elsevierStyleSup">9</span> Their influence in hormone secretion such as renin&#44; aldosterone&#44; atrial natriuretic peptide and insulin has been suggested in multiple occasions&#46; T-type channels are activated by short depolarisations&#44; which provoke a transitory flow of calcium&#46; In post-glomerular or efferent arterioles&#44; only T-type channels and no L-type channels are expressed and this implies that their tone must be controlled by T channels and AT1 angiotensin II receptors&#46; Manidipine and lercanidipine block T-type channels in efferent arterioles&#44; thus diminishing the intraglomerular pressure and also the excretion of albumin&#59; at the same time&#44; they block L-type channels&#44; favouring afferent arteriole dilation&#46; In this way&#44; T-type channel antagonists influence renal haemodynamics through their anti-hypertensive action&#46;<span class="elsevierStyleSup">9&#44;13-15</span> We can therefore consider their effect to be protective against renal damage&#44; since the kidney is one of the targets for end-organ damage in hypertensive and diabetic patients&#46;</p><p class="elsevierStylePara">Non-haemodynamic action of T-type channel antagonists may have multiple beneficial effects by inhibiting inflammatory processes &#40;inhibition of Rho kinase&#44; NF-kB&#44; leukocyte adhesion&#41; and blocking the renin-angiotensin system and the sympathetic nervous system&#46;<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Apart from L and T-type channels&#44; P&#47;Q type channels are found in the brain&#44; kidneys and pituitary gland &#40;&#91;Cav2&#46;1&#40;&#945;<span class="elsevierStyleInf">1A</span>&#41;&#93;&#44; N-type channels are found in the brain and nervous system &#40;Cav2&#46;2&#91;&#945;<span class="elsevierStyleInf">1B</span>&#93;&#41; and R-type channels in the brain&#44; heart and pituitary gland &#40;Cav2&#46;3&#91;&#945;<span class="elsevierStyleInf">1E</span>&#93;&#41;&#46;<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">MANIDIPINE&#44; ADIPOGENESIS AND INSULIN SENSITIVITY</span></p><p class="elsevierStylePara">The lipotoxicity hypothesis suggests that in type-2 diabetes the adipose tissue looses the ability to accommodate an excess of calories&#46; The loss of adipocyte differentiation causes the excess of calories to accumulate&#44; mainly in the liver&#44; pancreas and muscle tissue&#44; which contributes to the development of insulin resistance&#46;<span class="elsevierStyleSup">16</span> Small adipocytes are sensitive to insulin&#44; unlike the mature ones&#44; which become hypertrophied and insulin-resistant&#46;Therefore&#44; favouring adipogenesis will contribute to lowering insulin resistance in type-2 diabetics&#46;</p><p class="elsevierStylePara">The improvement of insulin sensitivity gained with dihydropyridine calcium antagonists is almost imperceptible&#46;</p><p class="elsevierStylePara">Nifedipine&#44; only blocks L-type channels&#44; worsens insulin resistance and inhibits the release of glucose&#46;<span class="elsevierStyleSup">4</span> However&#44; studies with manidipine show surprising results in this respect&#46; It has already been shown in a randomised clinical trial of 64 hypertensive patients with metabolic syndrome&#44; evaluated according to NCEP&#47;ATPIII criteria&#44; treated with manidipine or amlodipine during 12 weeks that although similar decreases in arterial pressure were observed with both treatments&#44; only the patients treated with manidipine show a significant reduction in insulin resistance&#46;<span class="elsevierStyleSup">17</span> Similarly&#44; the most recent analysis of the effects of the combination of delapril&#47;manidipine compared with olmesartan&#47;hydrochlorothiazide on insulin sensitivity and plasma fibrinogen in obese hypertensive patients showed that the first combination significantly reduced insulin resistance and plasma fibrinogen levels&#44; despite the fact that the decrease in arterial pressure values was similar for both combinations&#46;<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">Studies by others have shown that manidipine&#44; but not amlodipine or lercadipine&#44; activates the peroxisome proliferator-activated receptor &#40;PPAR&#947;&#41; in 3T3-L1 adipocytes in the rat&#46;<span class="elsevierStyleSup">19&#44;20</span> In our studies of NIH-3T3 cells treated with manidipine&#44; we observed an increase in the expression of both PPAR&#947; and the adipocyte differentiation 2 &#40;aP2&#41; gene&#46; The latter is an indicator of adipogenesis and possibly expressed after induction of the former &#40;figure 1&#41;&#46; These results suggest that manidipine increases insulin sensitivity in hypertensive diabetic patients by stimulating the formation of new adipocytes &#40;unpublished observations&#41;&#46; In addition it has been observed that the increase in intracellular calcium inhibits pre-adipocyte differentiation&#46;<span class="elsevierStyleSup">21</span> This is distinct from the well known role of calcium in more rapid processes&#44; such as neurosecretion&#44; excitation or contraction&#46;</p><p class="elsevierStylePara">Adipogenesis&#44; like other differentiation processes&#44; depends on transcription factor promoters such as PPAR&#947; and transcription factor inhibitors&#44; such as the GATA family&#44; which in turn are activated by extracellular signals&#46; Calcium homeostasis was studied with particular attention to the calreticulin&#44; the principal protein that binds to calcium in the lumen of the endoplasmic reticulum&#44; and which is largely responsible for rapid calcium exchange&#46; A study of stem cells and 3T3-L1 pre-adipocytes shows that calreticulin could modulate adipogenesis by means of a negative feedback mechanism&#46; PPAR&#947; is a potent calreticulin transcription activator&#44; since it binds to its promoter&#46; In this way&#44; it increases calreticulin expression&#44; but once calreticulin is over-expressed&#44; it inhibits cis binding of the PPAR&#947;-RxR heterodimer to PPAR&#947; response elements &#40;PPRE&#41;&#44; cancelling transcriptional activation of PPAR&#947; by fatty acids&#46; By this mechanism&#44; calreticulin negatively regulates both the expression of PPAR&#947; and other critical pro-adipogenic transcription factors such as C&#47;EBP&#945;&#46;<span class="elsevierStyleSup">22</span></p><p class="elsevierStylePara">The action of manidipine as a calcium channel blocker may prevent calcium from entering the cell thus&#44; decreasing the concentration of calcium in the endoplasmic reticulum and therefore&#44; the concentration of calreticulin&#44; favouring adipocyte differentiation&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MANIDIPINE&#58; ANTI-INFLAMMATORY&#44; VASOPROTECTIVE AND ANTIOXIDANT EFFECTS</span></p><p class="elsevierStylePara">Oxidative stress plays a fundamental role in the development of atherosclerosis&#46; Several studies demonstrate the beneficial effect of dihydropiridine calcium antagonists on atherosclerotic lesions&#46;<span class="elsevierStyleSup">23</span> The beneficial effects of calcium blockers in macrovascular endothelial cells should be demonstrated and proved using mechanisms that do not include calcium channels&#44; since these are not expressed in endothelial cells&#46;<span class="elsevierStyleSup">24</span> For this reason&#44; some authors have speculated that the action of dihydropyridines on this tissue was related with their lipophilic nature&#46;<span class="elsevierStyleSup">25</span> Toba et al&#46; point out the antioxidant&#44; anti-inflammatory effect of manidipine and other third-generation calcium antagonists such as amlodipine&#44; measured by the increase of expression of endothelial nitrous oxide synthase &#40;eNOS&#41; and the inhibition of the expression of angiotensin converter enzyme &#40;ACE&#41; &#44; but not by its possible action of lowering arterial pressure &#46; In this study&#44; we observe that manidipine normalises the decrease in both the eNOS gene and its protein&#44; and attenuates the over-expression of NAPDH oxidase&#44; VCAM and MCP-1 in the aorta of hypertensive rats&#46;<span class="elsevierStyleSup">26</span></p><p class="elsevierStylePara">Furthermore&#44; manidipine shows another beneficial effect on atherogenesis&#44; since it inhibits the expression of LOX-1&#44; a low-density lipoprotein receptor induced by angiotensin II&#46;<span class="elsevierStyleSup">27</span></p><p class="elsevierStylePara">Sun X et al<span class="elsevierStyleSup">28</span> recently showed that in differentiated mature adipocytes&#44; 3T3-L1 or co-cultures with both cell types&#44; calcitriol increases expression of inflammatory molecules such as MCP-1&#44; MIF&#44; M-CSF&#44; MIP&#44; IL-6&#44; TNF or CD14&#46; Treatment with nifedipine or dinitrophenol inhibits the action of the calcitriol&#44; which reveals a mechanism that is dependent on calcium and mitochondrial uncoupling&#46; Therefore&#44; it would seem that blocking calcium channels with manidipine would produce an antioxidant&#44; antiinflammatory effect by lowering the intracellular calcium level&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">KEY CONCEPTS</span></p><p class="elsevierStylePara">1&#46; Voltage-dependent calcium channels are classified according to their pharmacological and electrophysiological properties as L&#44; P&#47;Q&#44; N&#44; R and T-type&#46; They are composed of multiple heteromeric subunits&#58; &#945;&#44; &#946;&#44; &#947; and &#948;&#46; The &#945;1 subunit seems to be responsible for principal characteristic of these channels&#46;</p><p class="elsevierStylePara">2&#46; L-type channels are activated by intense depolarisations that are responsible for the tone of smooth arterial muscle&#46; Ttype channels are activated by short depolarisations&#44; which provoke a transitory flow of calcium&#46;</p><p class="elsevierStylePara">3&#46; Although the improvement in insulin sensitivity achieved with dihydropyridine calcium antagonists is almost imperceptible&#44; we have observed an increase in the relative expression of PPAR&#947; &#40;peroxisome proliferator-activated receptor&#41; and the relative expression of the adipocyte differentiation 2 &#40;aP2&#41; gene&#46; These preliminary results may suggest that manidipine increases insulin sensitivity in hypertensive diabetic patients by stimulating the formation of new adipocytes and preserving PPAR&#947; activity&#46;</p><p class="elsevierStylePara"><a href="grande&#47;17118078&#95;f1&#95;p205&#46;jpg" class="elsevierStyleCrossRefs"><img src="17118078_f1_p205.jpg"></img></a></p><p class="elsevierStylePara">Figure 1&#46; </p>"
    "pdfFichero" => "P-E-S-A171-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec440023"
          "palabras" => array:1 [
            0 => "Resistencia a la insulina"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec440025"
          "palabras" => array:1 [
            0 => "Manidipino"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec440027"
          "palabras" => array:1 [
            0 => "Calcioantagonistas"
          ]
        ]
      ]
      "en" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec440024"
          "palabras" => array:1 [
            0 => "Insulin resistance"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec440026"
          "palabras" => array:1 [
            0 => "Manidipine"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec440028"
          "palabras" => array:1 [
            0 => "Calcium antagonists"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Desde su introducci&#243;n en la d&#233;cada de los 70&#44; la evoluci&#243;n de los calcioantagonistas ha permitido solventar la incertidumbre inicialmente generada por aquellos f&#225;rmacos de primera generaci&#243;n&#46; &#201;stos se caracterizan por una menor disponibilidad oral&#44; una acci&#243;n vasodilatadora r&#225;pida y corta acci&#243;n&#46; El manidipino surge como un derivado dihidropirid&#237;nico de tercera generaci&#243;n con ventajas adicionales reales frente a las generaciones anteriores&#44; como son su alta lipofilicidad&#44; su acci&#243;n m&#225;s prolongada y una vida media prolongada a nivel del receptor y&#44; adem&#225;s&#44; algunas ventajas te&#243;ricas entre otras&#44; mejoras sobre la funci&#243;n renal reduciendo la presi&#243;n intraglomerular y la microalbuminuria&#46; Sin embargo&#44; la evaluaci&#243;n cl&#237;nica de estas &#250;ltimas propiedades depende a&#250;n de los resultados que se deriven de la experiencia cl&#237;nica&#46; Adem&#225;s de ahondar en su papel en la reducci&#243;n de la presi&#243;n arterial&#44; presentamos una breve revisi&#243;n sobre nuevos aspectos cardiometab&#243;licos de los calcioantagonistas dihidropirid&#237;nicos&#44; centr&#225;ndonos en el manidipino&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">From its introduction in the decade of the 70&#8217;s the evolution of the calcium channel blockers has allowed to resolve the uncertainty initially generated by those first generation drugs&#46; These&#44; are characterized by a smaller oral availability&#44; a fast vasodilator action and a short duration of action&#46; Manidipine arises as a dihydropyridine calcium antagonist of third generation with real additional advantages regarding to previous generations&#46; They show high lipophilia&#44; a more prolonged action and as well as a prolonged average life at the level of his receptor and&#44; in addition&#44; some theoretical advantages among others calcium antagonists&#44; improvements on the renal function by reducing the intraglomerular pressure and microalbuminuria&#46; Nevertheless&#44; the clinical evaluation of these last properties still depends on the results derived from clinical trials&#46; Besides to go deep in its role in their antihypertensive effect&#44; we presented a brief review on new cardiometabolic aspects of these dihydropyridines calcium antagonists focusing in manidipine&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "17118078_f1_p205.jpg"
            "Alto" => 434
            "Ancho" => 824
            "Tamanyo" => 24773
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:28 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J.Am.Board Fam.Med. 2008; 21: 562-568 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18988724" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Yoshinaga M, Sameshima K, Tanaka Y et al. Association between the number of cardiovascular risk factors and each risk factor level in elementary school children. Circ.J. 2008; 72: 1594-1597 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18756035" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern.Med. 2004; 43: 561-565 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15335180" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens.Res. 2008; 31: 43-50 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18360017" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65 Suppl 2: 29-39 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16398060" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N.Engl.J.Med. 1999; 341: 1447-1457"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J.Renin.Angiotensin.Aldosterone.Syst. 2008; 9: 1-9 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18404602" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ.Res. 2007; 100: 342-353 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17307972" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov NM. Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit. Proc.Natl.Acad.Sci.U.S.A 2006; 103: 17024-17029 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17071743" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Abernethy DR, Soldatov NM. Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. J.Pharmacol.Exp.Ther. 2002; 300: 724-728"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bergh JJ, Shao Y, Puente E, Duncan RL, Farach-Carson MC. Osteoblast Ca(2+) permeability and voltage-sensitive Ca(2+) channel expression is temporally regulated by 1,25-dihydroxyvitamin D(3). Am.J.Physiol Cell Physiol 2006; 290: C822-C831"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hayashi K, Wakino S, Homma K, Sugano N, Saruta T. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J.Pharmacol.Sci. 2005; 99: 221-227 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16293936" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Martinez Martin FJ. [Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine]. Nefrologia. 2007; 27 Suppl 6: 26-35 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18225601" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-779 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10720594" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12411451" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Martinez Martin FJ. Manidipne (but not amlodipine), increases insulin sensitivity and rises plasma adiponectin cocentrations in hypertensive non-diabetic patients with metabolic syndrome and impaired fasting glucose. Diabetologia 2005; 48 Suppl 1: A374"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern.Med. 2008; 47: 361-366 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18310964" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nakami T, Martinez MFJ. Manidipine prevents hepatic C-reactive protein production and reactive oxygen species generation by down-regulation of the age receptor expression, dependent on PPAR-gamma activation. Journal of Hypertension 2007; 25: S119-S120"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Oshimura H, Nakami T, Javier MF. Manidipine has a marked non-haemodynamic nephroprotective action; Partly dependent on PPAR-gamma activation, and synergistic with angiotensin receptor blockade. Journal of Hypertension 2007; 25: S8"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Meldolesi J. Inhibition of adipogenesis: a new job for the ER Ca2+ pool. J.Cell Biol. 2008; 182: 11-13 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18606853" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Szabo E, Qiu Y, Baksh S, Michalak M, Opas M. Calreticulin inhibits commitment to adipocyte differentiation. J.Cell Biol. 2008; 182: 103-116 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18606846" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Simon A, Levenson J. Effects of calcium channel blockers on atherosclerosis: new insights. Acta Cardiol. 2002; 57: 249-255 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12222691" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Adams DJ, Barakeh J, Laskey R, Van Breemen C. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J. 1989; 3: 2389-2400 <a href="http://www.ncbi.nlm.nih.gov/pubmed/2477294" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Berkels R, Breitenbach T, Bartels H et al. Different antioxidative potencies of dihydropyridine calcium channel modulators in various models. Vascul.Pharmacol. 2005; 42: 145-152 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15820440" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Toba H, Nakagawa Y, Miki S et al. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens.Res. 2005; 28: 689-700 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16392774" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Toba H, Shimizu T, Miki S et al. Calcium [corrected] channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens.Res. 2006; 29: 105-116 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16755144" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sun X, Zemel MB. Calcitriol and calcium regulate cytokine production and adipocyte-macrophage cross-talk. J.Nutr.Biochem. 2008; 19: 392-399 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17869082" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000002900000003/v0_201502091629/X2013251409004564/v0_201502091629/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35445"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Short Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000003/v0_201502091629/X2013251409004564/v0_201502091629/en/P-E-S-A171-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409004564?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 6 8 14
2024 October 52 320 372
2024 September 47 48 95
2024 August 63 68 131
2024 July 70 28 98
2024 June 63 34 97
2024 May 72 25 97
2024 April 59 27 86
2024 March 40 27 67
2024 February 51 41 92
2024 January 37 104 141
2023 December 36 31 67
2023 November 39 60 99
2023 October 48 39 87
2023 September 43 45 88
2023 August 36 30 66
2023 July 57 41 98
2023 June 86 32 118
2023 May 68 38 106
2023 April 60 20 80
2023 March 85 26 111
2023 February 44 22 66
2023 January 42 22 64
2022 December 55 25 80
2022 November 46 25 71
2022 October 60 39 99
2022 September 49 30 79
2022 August 52 47 99
2022 July 46 45 91
2022 June 45 21 66
2022 May 35 33 68
2022 April 57 49 106
2022 March 44 41 85
2022 February 55 38 93
2022 January 42 27 69
2021 December 31 35 66
2021 November 56 59 115
2021 October 48 53 101
2021 September 63 28 91
2021 August 66 40 106
2021 July 61 40 101
2021 June 42 18 60
2021 May 60 29 89
2021 April 120 30 150
2021 March 80 13 93
2021 February 85 20 105
2021 January 74 15 89
2020 December 34 4 38
2020 November 33 19 52
2020 October 16 5 21
2020 September 24 9 33
2020 August 36 11 47
2020 July 47 9 56
2020 June 45 7 52
2020 May 42 11 53
2020 April 37 7 44
2020 March 43 14 57
2020 February 32 11 43
2020 January 57 20 77
2019 December 52 15 67
2019 November 65 16 81
2019 October 61 10 71
2019 September 40 6 46
2019 August 29 10 39
2019 July 27 22 49
2019 June 15 6 21
2019 May 24 1 25
2019 April 49 20 69
2019 March 15 14 29
2019 February 24 8 32
2019 January 26 18 44
2018 December 59 24 83
2018 November 55 11 66
2018 October 58 8 66
2018 September 51 7 58
2018 August 26 18 44
2018 July 30 5 35
2018 June 28 9 37
2018 May 24 13 37
2018 April 20 7 27
2018 March 30 8 38
2018 February 27 6 33
2018 January 30 8 38
2017 December 35 7 42
2017 November 28 9 37
2017 October 32 12 44
2017 September 27 10 37
2017 August 33 15 48
2017 July 22 8 30
2017 June 47 17 64
2017 May 31 10 41
2017 April 28 10 38
2017 March 14 20 34
2017 February 22 15 37
2017 January 22 10 32
2016 December 63 6 69
2016 November 81 14 95
2016 October 68 17 85
2016 September 113 17 130
2016 August 189 10 199
2016 July 142 11 153
2016 June 120 0 120
2016 May 135 0 135
2016 April 89 0 89
2016 March 70 0 70
2016 February 91 0 91
2016 January 84 0 84
2015 December 98 0 98
2015 November 63 0 63
2015 October 59 0 59
2015 September 69 0 69
2015 August 60 0 60
2015 July 58 0 58
2015 June 24 0 24
2015 May 55 0 55
2015 April 6 0 6
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?